Personalis, Inc. (PSNL)

Several events have impacted Personalis, Inc.'s stock price in the past six months. Personalis reported Q1 2025 revenue of $20.6 million, a 6% increase year-over-year, driven by a 39% increase in biopharma revenue. Personalis announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA), demonstrating NeXT Personal's significantly higher sensitivity in detecting circulating tumor DNA (ctDNA) compared to another gene-mutation based test, contributing to a stock surge. Personalis and Tempus AI, Inc. expanded and extended their strategic collaboration for cancer recurrence detection technology through 2029. A workforce reduction of approximately 20% in late 2023 was expected to extend the company's cash runway into 2026. Analysts have maintained "Buy" recommendations and adjusted price targets. Cathie Wood's ARK ETFs have been actively trading PSNL, with reports of selling shares in October 2025.

Based on the available information, there is no indication of significant demand seasonality for Personalis, Inc.'s products and services. The company's focus on cancer genomic tests and research suggests a relatively stable demand throughout the year rather than pronounced seasonal fluctuations.

Personalis, Inc. is a precision oncology company focused on transforming cancer treatment through genomic tests and analytics. They operate in the Health Care sector, specifically Biotechnology & Medical Research and Life Sciences Tools and Services, with a focus on Diagnostics & Research and Medical Specialties. Their major products and services include NeXT Personal, ImmunoID NeXT, NeXT Personal Dx, NeXT Dx, Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS). Personalis' services are utilized by pharmaceutical and biopharmaceutical companies for translational research, biomarker discovery, personalized cancer therapy development, and clinical trials. Physicians also use their tests to detect residual or recurrent cancer, monitor therapy response, and gain insights for therapy selection.

Personalis, Inc. is headquartered in Fremont, California, United States. The company has an operational presence in both the United States and the United Kingdom, and it serves customers internationally.

Personalis, Inc.'s brand reputation appears to be positively influenced by its advancements in cancer genomics and strategic collaborations. News and reports primarily highlight successful clinical trial data and the expansion of partnerships like the one with Tempus AI. These developments underscore the company's innovative approach to personalized medicine and its potential to improve cancer detection and treatment outcomes. No specific negative events or controversies impacting Personalis' brand reputation have been reported in the past year.

Personalis, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold a significant portion, ranging from approximately 53.81% to 69.36% of the company's stock. Major institutional owners include Merck & Co., Inc., Lightspeed Management Company, L.L.C., ARK Investment Management LLC, BlackRock, Inc., AIGH Capital Management LLC, Vanguard Group Inc, Standard Life Aberdeen plc, Blue Water Life Science Advisors, LLC, Geode Capital Management, Llc, T. Rowe Price Investment Management, Inc., and Tempus AI, Inc.. Euan A. Ashley is recognized as one of the co-founders of Personalis Inc.